257 related articles for article (PubMed ID: 15234570)
41. [Current approaches of treatment for myelodysplastic syndrome (MDS)].
Lewandowski K; Goździk J; Hansz J
Acta Haematol Pol; 1995; 26(4):333-41. PubMed ID: 8571734
[TBL] [Abstract][Full Text] [Related]
42. Characteristics of the phenotypic abnormalities of bone marrow cells in childhood myelodysplastic syndromes and juvenile myelomonocytic leukemia.
Oliveira AF; Tansini A; Vidal DO; Lopes LF; Metze K; Lorand-Metze I
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27748021
[TBL] [Abstract][Full Text] [Related]
43. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome.
Woodard P; Barfield R; Hale G; Horwitz E; Leung W; Ribeiro R; Rubnitz J; Srivistava DK; Tong X; Yusuf U; Raimondi S; Pui CH; Handgretinger R; Cunningham JM
Pediatr Blood Cancer; 2006 Dec; 47(7):931-5. PubMed ID: 16155933
[TBL] [Abstract][Full Text] [Related]
44. Impact on survival of different treatments for myelodysplastic syndromes (MDS).
Nachtkamp K; Kündgen A; Strupp C; Giagounidis A; Kobbe G; Gattermann N; Haas R; Germing U
Leuk Res; 2009 Aug; 33(8):1024-8. PubMed ID: 19185917
[TBL] [Abstract][Full Text] [Related]
45. Allogeneic stem cell transplantation for myelodysplastic syndromes in children: a report from the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Díaz-Heredia C; Badell I; Bureo E; Gómez P; Martínez A; Verdeguer A; Pérez-Hurtado JM; Fernández-Delgado R; González-Vicent M; Maldonado MS
Pediatr Hematol Oncol; 2009; 26(5):345-55. PubMed ID: 19579081
[TBL] [Abstract][Full Text] [Related]
46. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
[TBL] [Abstract][Full Text] [Related]
47. Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.
Abdelhameed A; Pond GR; Mitsakakis N; Brandwein J; Chun K; Gupta V; Kamel-Reid S; Lipton JH; Minden MD; Schimmer A; Schuh A; Yee K; Messner HA
Cancer; 2008 Apr; 112(7):1513-21. PubMed ID: 18286528
[TBL] [Abstract][Full Text] [Related]
48. Myelodysplastic syndromes clinical practice guidelines in oncology.
Greenberg PL; Baer MR; Bennett JM; Bloomfield CD; De Castro CM; Deeg HJ; Devetten MP; Emanuel PD; Erba HP; Estey E; Foran J; Gore SD; Millenson M; Navarro WH; Nimer SD; O'Donnell MR; Saba HI; Spiers K; Stone RM; Tallman MS
J Natl Compr Canc Netw; 2006 Jan; 4(1):58-77. PubMed ID: 16403405
[No Abstract] [Full Text] [Related]
49. Non-hematopoietic stem cell transplantation treatment of juvenile myelomonocytic leukemia: a retrospective analysis and definition of response criteria.
Bergstraesser E; Hasle H; Rogge T; Fischer A; Zimmermann M; Noellke P; Niemeyer CM
Pediatr Blood Cancer; 2007 Oct; 49(5):629-33. PubMed ID: 16991133
[TBL] [Abstract][Full Text] [Related]
50. Predictors of outcome following myeloablative allo-SCT for therapy-related myelodysplastic syndrome and AML.
Nevill TJ; Hogge DE; Toze CL; Nantel SH; Power MM; Abou Mourad YR; Song KW; Lavoie JC; Forrest DL; Barnett MJ; Shepherd JD; Nitta JY; Wong S; Sutherland HJ; Smith CA
Bone Marrow Transplant; 2008 Nov; 42(10):659-66. PubMed ID: 18679372
[TBL] [Abstract][Full Text] [Related]
51. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome.
Schmid C; Schleuning M; Ledderose G; Tischer J; Kolb HJ
J Clin Oncol; 2005 Aug; 23(24):5675-87. PubMed ID: 16110027
[TBL] [Abstract][Full Text] [Related]
52. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
[TBL] [Abstract][Full Text] [Related]
53. Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N; Shimoni A; Zabelina T; Schieder H; Panse J; Ayuk F; Wolschke C; Renges H; Dahlke J; Atanackovic D; Nagler A; Zander A
Bone Marrow Transplant; 2006 Feb; 37(4):339-44. PubMed ID: 16415898
[TBL] [Abstract][Full Text] [Related]
54. Update on the therapy for myelodysplastic syndrome.
Kasner MT; Luger SM
Am J Hematol; 2009 Mar; 84(3):177-86. PubMed ID: 19195035
[TBL] [Abstract][Full Text] [Related]
55. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.
Oliansky DM; Antin JH; Bennett JM; Deeg HJ; Engelhardt C; Heptinstall KV; de Lima M; Gore SD; Potts RG; Silverman LR; Jones RB; McCarthy PL; Hahn T
Biol Blood Marrow Transplant; 2009 Feb; 15(2):137-72. PubMed ID: 19167676
[TBL] [Abstract][Full Text] [Related]
56. A patient-oriented approach to treatment of myelodysplastic syndromes.
Cazzola M; Anderson JE; Ganser A; Hellström-Lindberg E
Haematologica; 1998 Oct; 83(10):910-35. PubMed ID: 9830800
[TBL] [Abstract][Full Text] [Related]
57. Toxicity and outcome of children with treatment related acute myeloid leukemia.
Tabori U; Revach G; Nathan PC; Strahm B; Rachlis A; Shago M; Grant R; Doyle J; Malkin D
Pediatr Blood Cancer; 2008 Jan; 50(1):17-23. PubMed ID: 17252569
[TBL] [Abstract][Full Text] [Related]
58. Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia.
Bell JA; Galaznik A; Huelin R; Stokes M; Guo Y; Fram RJ; Faller DV
Clin Lymphoma Myeloma Leuk; 2018 Apr; 18(4):e157-e166. PubMed ID: 29475821
[TBL] [Abstract][Full Text] [Related]
59. Sustained remissions of high-risk acute myeloid leukemia and myelodysplastic syndrome after reduced-intensity conditioning allogeneic hematopoietic transplantation: chronic graft-versus-host disease is the strongest factor improving survival.
Valcárcel D; Martino R; Caballero D; Martin J; Ferra C; Nieto JB; Sampol A; Bernal MT; Piñana JL; Vazquez L; Ribera JM; Besalduch J; Moraleda JM; Carrera D; Brunet MS; Perez-Simón JA; Sierra J
J Clin Oncol; 2008 Feb; 26(4):577-84. PubMed ID: 18086801
[TBL] [Abstract][Full Text] [Related]
60. The role of splenectomy in children with juvenile myelomonocytic leukemia.
Ozyürek E; Cetin M; Tuncer M; Hiçsönmez G
Turk J Pediatr; 2007; 49(2):154-7. PubMed ID: 17907514
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
